Neurocrine Biosciences, Inc. NBIX
Regular-session close
After hours · Nov 20, 5:23 PM ET
- YTD
- +6.16%
- 1 year
- +8.34%
Held by funds
318 US ETFs and mutual funds hold NBIX · largest positions
- IJH 0.51% of fund $608.07M
- NJH 0.44% of fund $511.36M
- VTI 0.02% of fund $373.07M
- VB 0.18% of fund $332.96M
- VBK 0.43% of fund $186.23M
- VXF 0.18% of fund $168.47M
- XBI 1.67% of fund $161.73M
- VFLO 1.05% of fund $131.18M
- IBB 1.19% of fund $130.89M
- MDY 0.51% of fund $126.78M
- FBT 3.87% of fund $115.09M
- USMV 0.47% of fund $114.26M
- XMHQ 1.98% of fund $112.09M
- IJK 1.03% of fund $104.01M
- SPMD 0.51% of fund $92.69M
- NNK 0.84% of fund $91.65M
- NIW 0.45% of fund $91.00M
- VEXRX 0.41% of fund $90.87M
- IWP 0.46% of fund $79.91M
- IWR 0.12% of fund $70.30M
Ownership
Top institutional holders
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 14.68% | 14,856,103 | 2.24B | Sep 29, 2026 |
| Dodge & Cox Inc. | 5.44% | 5,504,578 | 828.82M | Sep 29, 2026 |
| JPMORGAN CHASE & CO | 5.23% | 5,292,589 | 796.91M | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 5.00% | 5,060,036 | 761.89M | Sep 29, 2026 |
| State Street Corporation | 4.75% | 4,807,975 | 723.94M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 4.53% | 4,580,803 | 689.73M | Sep 29, 2026 |
Top mutual fund holders
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Dodge & Cox Funds-Dodge & Cox Stock Fund | 3.92% | 3,964,000 | 596.86M | Jun 29, 2026 |
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3.58% | 3,620,760 | 545.18M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.15% | 3,193,267 | 480.81M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.28% | 2,304,996 | 347.06M | Jun 29, 2026 |
| J.P. Morgan Mutual Fd. Investment TRT-JPMorgan Growth Advantage Fd. | 1.34% | 1,358,475 | 204.55M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.31% | 1,329,829 | 200.23M | Jun 29, 2026 |
Included in Plus and up
Sign in to see Institutional ownership
How much funds own from their 13F filings, quarter by quarter, and the largest holders.
Free with an account
Sign in to see Insider activity
Two years of insider buying and selling by month, marked on the price.
Included in Plus and up
Sign in to see Congress trading
Every stock trade disclosed by members of the US Senate and House.
Leadership team
Who runs NBIX, and what each was last paid
Kyle W. Gano, President, CEO & DirectorAverage age 63
| Name | Title | Pay | Age |
|---|---|---|---|
| Kyle W. Gano | President, CEO & Director | $1.95M | 53 |
| Jude Onyia | Chief Scientific Officer | $1.41M | 62 |
| Eiry Wyn Roberts | Chief Medical Officer | $1.32M | 62 |
| Sanjay Keswani MBBS | Chief Medical Officer | $1.32M | 55 |
| Matthew C. Abernethy | Chief Financial Officer | $1.31M | 46 |
| Eric S. Benevich | Chief Commercial Officer | $1.19M | 61 |
| Wylie W. Vale | Co-Founder | $47.0K | 84 |
| Todd Tushla | Vice President of Investor Relations | — | — |
| Lawrence Steinman | Co-Founder of Neurocrine | — | 78 |
| Aaron Vosburgh | Senior Vice President of Finance & Accounting | — | — |
| Lewis Choi | Chief Information Officer | — | — |
Pay is the latest total FMP has for each person (salary, bonus, stock and other awards) and can lag the newest proxy statement. Source: Financial Modeling Prep, from the company’s SEC filings.
Free with an account
Sign in to see CEO compensation
What the chief executive was paid each year, by salary, bonus and stock, beside the company's earnings.
Free with an account
Sign in to see Board of directors
Who sits on the board, who chairs it, and how long each director has served.
Insiders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ABERNETHY MATTHEW C | Chief Financial Officer | Sale | Sep 13, 2026 | 42,808 |
| BENEVICH ERIC S. | Officer | Stock Award(Grant) | Sep 10, 2026 | 67,297 |
| COOKE JULIE SMITH | Officer | Stock Award(Grant) | Sep 10, 2026 | 24,025 |
| GANO KYLE W | Chief Executive Officer | Conversion of Exercise of derivative security | Oct 29, 2026 | 155,010 |
| GORMAN KEVIN CHARLES | Director | Stock Award(Grant) | Sep 10, 2026 | 517,797 |
| LIPPOLDT DARIN M | Officer | Stock Award(Grant) | Sep 10, 2026 | 56,793 |
